Results 101 to 110 of about 7,897,516 (385)

Considerations on Clinical Development and Regulatory of the Oversea License-in 
Anti-tumor Drugs

Chinese Journal of Lung Cancer, 2022
With the boom of China's innovative pharmaceutical industry, licensing-in model has gradually become an important research and development model for innovative pharmaceutical companies.
Xiao ZHAO, Ruimin HAO, Xin TONG, Limin ZOU, Ling TANG, Hong ZHANG, Lin XIA, Zhimin YANG   +7 more
doaj   +1 more source

Reduced Efficacy of Praziquantel Against Schistosoma mansoni Is Associated With Multiple Rounds of Mass Drug Administration

Clinical Infectious Diseases, 2016
The efficacy of praziquantel against Schistosoma mansoni was significantly lower in Ugandan schools that had received more prior rounds of mass drug administration, as determined by fitting a statistical model to parasite egg counts before and after ...
Thomas Crellen, M. Walker, P. Lamberton, N. Kabatereine, E. Tukahebwa, J. Cotton, J. Webster   +6 more
semanticscholar   +1 more source

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

On drug transport after intravenous administration [PDF]

arXiv, 2011
A mathematical model of a drug transport after rapid injection is given. It takes into account three processes: - drug plasma protein binding in central compartment - transport processes between the central compartment and the peripheral compartment - elimination of a drug from the central compartment. .
arxiv  

Use of data mining at the Food and Drug Administration

J. Am. Medical Informatics Assoc., 2016
OBJECTIVES This article summarizes past and current data mining activities at the United States Food and Drug Administration (FDA). TARGET AUDIENCE We address data miners in all sectors, anyone interested in the safety of products regulated by the FDA (
H. Duggirala, Joseph M. Tonning, Ella S Smith, R. Bright, J. Baker, R. Ball, Carlos Bell, S. Bright-Ponte, Taxiarchis Botsis, Khaled Bouri, M. Boyer, K. Burkhart, G. S. Condrey, James J. Chen, S. Chirtel, Ross W. Filice, H. Francis, Hongying Jiang, Jonathan G. Levine, David Martin, T. Oladipo, Rene O'Neill, L. A. Palmer, Antonio Paredes, George Rochester, D. Sholtes, A. Szarfman, H. Wong, Zhiheng Xu, Taha A. Kass-Hout   +29 more
semanticscholar   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

The di-flavoenzyme reductase directly activates oxygen for the metabolism of diverse drug molecules by liver microsomal Cytochrome P450s [PDF]

arXiv, 2006
This submission has been withdrawn by arXiv administration due to complaints of misuse of institutional affiliation.
arxiv  

A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini, Ezgi Oner, Mark P. Ward, Sinead Hurley, Brian David Henderson, Faye Lewis, Stephen P. Finn, Gerard J. Fitzmaurice, John J. O'Leary, Sharon O'Toole, Lorraine O'Driscoll, Kathy Gately   +11 more
wiley   +1 more source

Valuation implications of pharmaceutical companies' R&D regulatory approval notifications [PDF]

, 2013
This paper examines shareholder wealth effects surrounding applications to, and approvals by, the United States Food and Drug Administration (FDA) for firms listed on the New York (NYSE) and London (LSE) stock exchanges.
Hamill, P.A., McIlkenny, P., Opong, K.K.
core   +1 more source